Associate
Xirui has worked on over 20 inter partes review (IPR) proceedings, representing both petitioners and patent owners. She has experience searching prior art, developing validity strategy, crafting effective briefing, preparing expert and lay witnesses, and arguing in oral hearing.
Xirui's practice extends to evaluations for diligence, clearance, landscape, freedom-to-operate, and design-around assessments. She provides legal opinions on infringement, validity, and patentability. Xirui also advises clients through all stages of preparation and prosecution of U.S. utility and design patent applications, including handling invention disclosures; preparing new and continuing patent applications; responding to office actions; preparing and filing appeals to the PTAB; and managing domestic and international portfolios aligned with client business goals.
Xirui's experience spans numerous technologies, including medical and analytical devices, optical microscopy and spectroscopy, optical biosensing, optoelectronics, optical coherence tomography, endoscopy, magnetic resonance imaging, ultrasound imaging, image and video processing, nanotechnology, in vitro molecular diagnostics, consumer electronics, mobile devices, digital camera, electronic authentication, LED lighting systems, robotics, neurostimulation and neuromodulation, 3D printing and additive manufacturing, virtual and augmented reality, computer processor, power tools, and artificial intelligence (AI) technologies in medicine.
Before joining Finnegan, Xirui completed her doctoral research in the Optical Characterization and Nanophotonics (OCN) laboratory at the Photonics Center of Boston University, where she built high-throughput optical biosensing instruments for molecular research and point-of-care diagnosis.Her collaboration with scientists and engineers during her studies strengthens her ability to work with inventors and experts on technical intricacies in her patent practice.
Articles
Trending at the PTAB: 6 Areas to Watch in 2024 Trending at the PTAB: 6 Areas to Watch in 2024
January 2, 2024
Law360Articles
How the PTAB Landscape Shifted in 2023 How the PTAB Landscape Shifted in 2023
December 15, 2023
Law360Articles
Negotiating AI-Life Sciences Partnerships to Minimize IP Risk Negotiating AI-Life Sciences Partnerships to Minimize IP Risk
August 4, 2023
Law360Event
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology Patent Law Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology Patent Law
April 27, 2023
Cambridge
Articles
Strategic Intellectual Property Considerations for Protecting AI Innovations in Life Sciences Strategic Intellectual Property Considerations for Protecting AI Innovations in Life Sciences
January 2023
International Pharmaceutical IndustryWebinar
U.S. Medical Device Patent Strategies and Patent Eligibility U.S. Medical Device Patent Strategies and Patent Eligibility
September 17, 2020
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.